BlackRock Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

BlackRock Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.81M	Sell	36,199 -3,907	-10%	-$205K	﹤0.01%	1559
2016 Q3	$2.1M	Sell	40,106 -2,620	-6%	-$125K	﹤0.01%	1450
2016 Q2	$1.77M	Buy	42,726 +2,455	+6%	+$107K	﹤0.01%	1485
2016 Q1	$1.64M	Sell	40,271 -16,650	-29%	-$572K	﹤0.01%	1518
2015 Q4	$2.36M	Sell	56,921 -32,473	-36%	-$1.09M	﹤0.01%	1347
2015 Q3	$1.38M	Sell	89,394 -1,338	-1%	-$28.8K	﹤0.01%	1512
2015 Q2	$2.25M	Sell	90,732 -29,588	-25%	-$659K	﹤0.01%	1222
2015 Q1	$2.75M	Buy	120,320 +14,120	+13%	+$356K	﹤0.01%	1113
2014 Q4	$2.87M	Buy	106,200 +99,260	+1,430%	+$1.71M	﹤0.01%	1097
2014 Q3	$81K	Sell	6,940 -505	-7%	-$6.37K	﹤0.01%	3118
2014 Q2	$116K	Buy	7,445 +3,665	+97%	+$52.6K	﹤0.01%	2976
2014 Q1	$74K	Sell	3,780 -2,605	-41%	-$44.2K	﹤0.01%	3149
2013 Q4	$107K	Buy	+6,385	New	+$79.3K	﹤0.01%	3011

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's FPRX Position: Q4 2016 in Review

BlackRock Advisors reduced its Five Prime Therapeutics, Inc. (FPRX) stake by 9.7% in Q4 2016, selling an estimated $205K and leaving 36,199 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1559.

BlackRock Advisors first reported a position in FPRX in Q4 2013 and has held it in 13 quarters since. The position peaked at $2.87M in Q4 2014. 172 funds tracked by Wall St. Rank hold FPRX as of Q4 2016.

BlackRock Advisors held 36,199 shares of Five Prime Therapeutics, Inc. worth $1.81M as of Q4 2016.
BlackRock Advisors sold 3,907 Five Prime Therapeutics, Inc. shares in Q4 2016, an estimated $205K.
Five Prime Therapeutics, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1559 holding.
BlackRock Advisors first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and has held it in 13 quarters since.
BlackRock Advisors's Five Prime Therapeutics, Inc. position peaked at $2.87M in Q4 2014.
172 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.